Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics - Poll - MDSpire

Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics

  • By

  • Fuliang Li

  • Hongmei Li

  • Dulguun Juramt

  • Kai Kou

  • Frank Tacke

  • Lanlan Chen

  • July 2, 2026

  • 0 min

Share

Original Source(s)

Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics

  • by Fuliang Li, Hongmei Li, Dulguun Juramt, Kai Kou, Frank Tacke, Lanlan Chen

  • July 2, 2026

Related Content

Histopathological Findings in Sleeve Gastrectomy Specimens: Prevalence, Determinants, and Clinical Implications in a Large Brazilian Cohort

To Fix or Not to Fix: Effect of Gastropexy on Esophageal Manometric Values Post Laparoscopic Sleeve Gastrectomy

Correction to: One Anastomosis Gastric Bypass Versus Single Anastomosis Sleeve Jejunal Bypass: Does Duodenal Exclusion Matter?